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OBJECTIVES: to explore the effects of patient self-testing (PST) of oral anticoagula-
tion therapy (OAT) by CoaguChek® XS System compared to standard available care
(laboratory testing) for selected group of patients. METHODS: Health Economy
Model (HECON), using Cost-Effectiveness Analysis (CEA), complemented by Bud-
get-Impact Analysis (BIA) on public health insurance coverage in Slovakia. We
searched MEDLINE, Cochrane and available grey literature (Industrial Sources and
Expert Opinions) for meta analyses, systematic reviews, economic evaluation stud-
ies and health technology reports on PST of OAT. Outcomes analyzed were feasi-
bility and accuracy of PST, thromboembolic events, hemorrhagic complications
and mortality. Real-world data from General Health Insurance, Inc. were used for
costs associated with corresponding diagnoses, complications and management of
patients on OAT, including full cohort of patients (n100, average age of 63 years)
on PST. Markov Model (life time horizon) for OAT patient management was devel-
oped, comparing PST with standard care. Outcomes observed were major throm-
boembolic events, major hemorrhagic complications and mortality. Payer perspec-
tive and direct healthcare costs only, associated with OAT management were
considered in CEA and BIA for diagnosis subgroups. Discount rate of 5% was used
for costs as well as outcomes. Sensitivity analysis for major complications was
performed. RESULTS: CEA for PST vs. standard care associated with OAT shows
that intervention is cost-effective (dominant) for all diagnosis subgroups. Net costs
(BIA) associated with PST for expanding the existing cohort of patients 10 times
(n1000) are 1.596 mil. € in Year 1 (up to 3.579 € in Year 5). CONCLUSIONS: PST of
OAT is considered cost-effective in terms of International Normalized Ratio (INR)
regulation and safer in terms of complications. Moreover, analysis of selected sub-
populations (mitral and/or aortic mechanical heart valve implantation, aortic
and/or other aneurysm and congenital cardiovascular malformations) shows that
PST brings the most significant cost-savings especially for those OAT patient seg-
ments.
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ARE HEALTH TECHNOLOGY ASSESSMENTS OF MEDICAL DEVICES CATCHING
UP WITH PHARMACEUTICALS?
Sweeney N, Andreykiv M, Wiebinga C
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To evaluate how HTA is applied to medical devices (MD) and to assess
whether established HTA agencies have similar influences over MD coverage and
reimbursement decisions compared to pharmaceuticals. METHODS: Manual
search of 69 HTA agencies’ websites was conducted to determine whether they
undertake MD HTAs. Of the agencies that reported MD assessments, we evaluated
the HTA process in respect to methodological approaches and influence on market
access decisions. RESULTS:The majority (49 out of 69) of HTA agencies conduct MD
assessments and make these appraisals publically available. Thirty-five of these
agencies provide reimbursement advice in their reports. In most cases recommen-
dations serve as non-mandatory guidance, aimed at helping local and national
stakeholders make informed decisions about the use of the device within their
health care system. Despite widespread use of MD evaluations, the number of
completed reviews is relatively low. Sixty percent of the agencies that performed
MD HTAs (29 out of 49) applied similar methodologies to both MD and drug
assessments. CONCLUSIONS: While the majority of HTA agencies are adding MD
assessments to their work plans, procedural pathways are not as transparent and
robust as those for pharmaceuticals. Combined with the low output of publications
this currently leads to limited application of MD HTAs to market access decisions.
However, a new system is emerging which recognizes the unique features of MD
and the distinctive level of evidence needed for regulatory approval. In future we
anticipate that market access of medical devices will be centralized under the
umbrella of existing HTA agencies. Thus, following the example of NICE, HAS and
CVZ which have established one national HTA process, with independent path-
ways within their agencies for both drug and MDs.
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OBJECTIVES: The objectives of this paper are to present the current status of HTA
in the field of radiology and describe the role played by Chilean Health System
governmental institutions and private agents in the decision-making process in
order to allocate resources for the incorporation of new technology. METHODS: A
bibliographical review was made based on the opinions of local experts, and a
review of the available local literature. RESULTS: The decision-making process of
acquiring a new technology in radiology is different depending on whether the
provider is public or private. For public providers, first, the hospital solicits to
include the purchase of the equipment in the budget for the year immediately
following. Then, the decision is taken by the Ministry of Health (MINSAL). It is a
centralized decision, but not subdue to a formal economic assessment. For private
providers, the decision usually comes from the clinical need. An economic assess-
ment for viability is carried out, expected demand and budgeted costs of examina-
tion are calculated in order to calculate the payback time on investment and finally
decision to purchase is made. CONCLUSIONS: Data on health economics are in-
creasingly important to the Chilean health authorities, even though, they are not
considered essential to make decisions. At present, there is more awareness of the
importance of implementing methods of analysis. Therefore, it is advisable to
continue providing such information. On the whole, the decision to purchase a new
technology in radiology depends on whether the provider is public or private. It
does not involve variables derived from complex economic or structured studies,
but depends on the need of the equipment and market availability.
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OBJECTIVES: Skull Deformaty (SD) is a flattening of the head as a result of pressure
on the malleable skull in infants in the first months of life. Presently, a RCT is
conducted to compare the effect of an orthotic helmet to the natural recovery of
skull shape in the first three years of life. Burden of treatment is considerable; the
helmet has to be worn 23 hours a day for at least 6 months. Possible harms include
acceptation problems, pressure wounds and severe skin rash or eczema. The
harms of treatment are perceived as an important reason for low adherence to and
parental refusal of helmet treatment. The objective of this study is to estimate the
risk-benefit trade-off in SD management in pediatric physiotherapists. METHODS:
A discrete choice experiment was performed with the most important attributes of
SD management. A total of 267 pediatric physiotherapists stated their preference
for treatment of a 5 month old child with SD. A three scenario design was chosen
Each scenario was characterized by its effect, its burden and the harms of treat-
ment. Logistical regression analysis was performed to analyze the results of the
discrete choice experiment. RESULTS: Not surprisingly, child physiotherapists’
ideal treatment has a high probability of timely success with low burden and min-
imal harms. At present, most attributes indicate a strong preference for awaiting
natural recovery. Risk benefit assessment favoring the helmet will only be attained
if the helmet can show highly significant clinical benefit. CONCLUSIONS: This
study shows that risk benefit analysis can give early indications on the potential of
a treatment, by estimating the effectiveness at which the treatment becomes more
favorable than its comparator. Whether the risk-benefit analysis will be in favor of
helmet treatment in the case of SD, is questionable, as earlier studies have not
demonstrated superiority of the helmet.
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OBJECTIVES: There is increasing interest in estimating the health and economic
impact of a new technology in the early phases of its development. However, this
requires knowledge about current care. We examined how non-invasive imaging is
currently used to assess carotid stenosis in patients with a recent TIA or minor
ischemic stroke, as a first step in an early economic evaluation of new imaging
technologies which will be used for the prediction of the risk of plaque rupture.
METHODS: We first examined the current guidelines in the The Netherlands, Eu-
rope and US regarding the use of non-invasive imaging tests (i.e. CT angiography
(CTA), duplex ultrasonography (DUS), MR angiography (MRA)) in the assessment of
carotid stenosis in patients with a TIA or minor ischemic stroke. In addition, semi-
structured interviews were conducted with neurologists in several Dutch hospitals
to determine how patients are actually diagnosed in daily clinical practice.
RESULTS: Current guidelines differ in the use of non-invasive imaging tests in
assessing carotid stenosis in patients with a recent TIA or minor ischemic stroke. In
addition, practice variation is high, since hospitals use different (combinations of)
tests. According to the neurologists, these differences are probably caused by ca-
pacity problems, degree of expertise in performing certain tests and lack of evi-
dence regarding effectiveness and cost-effectiveness of the imaging tests in assess-
ing carotid stenosis. CONCLUSIONS: The observed practice variation is high, and
has implications for assessing the health and economic impact of the new tech-
nology, since estimating impact requires comparison with current care. The choice
of just one comparator representing current care is therefore meaningless, since
choice of comparator may strongly affect the estimated health and economic im-
pact of the new technology. The final impact of a new technology will be hospital-
dependent, and therefore multiple comparisons and scenario analyses are needed.
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SURGICAL COHORTS USING A RETROSPECTIVE NATIONWIDE PATIENT
DATABASE
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OBJECTIVES: Several observational studies have examined the epidemiological
and social characteristics of patients undergoing hernia surgery, but conclusions
drawn from these studies are generally limited due to the small sample population.
Here we describe patient demographics of hernia repair patients and surgical ex-
penditure using a population-based approach with a retrospective nationwide
database. METHODS: Premier Inc has established one of the largest hospital data-
bases worldwide. It collects patient data from around 500 hospitals in the US.
Hernia surgery was stratified by inpatient or outpatient treatment, hernia repair
surgery type (inguinal, incisional or umbilical), surgical procedure (laparoscopic or
open), and the type of mesh used (flat, tissue-separating or device). Patient demo-
graphics were recorded and are presented for every cohort of patients. Surgical
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